allogeneic anti-HA-2 TCR-engineered T cells TSC-101

A preparation of donor-derived T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for HLA-A*02:01-restricted minor histocompatibility antigen HA-2 (HA2), with potential immunomodulating and antineoplastic activities. Following allogeneic haploidentical hematopoietic cell transplantation (HCT) in HLA-A*02:01 positive patients, allogeneic anti-HA-2 TCR-engineered T cells TSC-101 specifically recognize and bind to HA-2 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing HA-2. HA-2 is a lineage-specific antigen found on leukemia cells.